Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear transcription factor Y subunit alpha (NFYA) is an essential component of the highly conserved NF-Y trimeric transcription factor complex, together with NF-YB and NF-YC[1][4][5][2][7]. The NF-Y complex specifically recognizes and binds to CCAAT box motifs found in the promoters of a wide array of genes, acting as a sequence-specific DNA binding factor and a pioneer factor that increases chromatin accessibility for other transcription regulators[1][2][4]. NFYA provides the sequence specificity and regulatory function of the complex, contains a glutamine-rich transactivation domain, and participates in transcriptional regulation critical for cell cycle control, DNA damage response, and proliferation[4][1][5]. While implicated in cancer and other diseases through its regulation of gene expression, NFYA is not a direct therapeutic target in current clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear transcription factor Y subunit alpha (NFYA).